Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Healthy Extracts (HYEX) Cash & Equivalents (2016 - 2025)

Healthy Extracts (HYEX) has 11 years of Cash & Equivalents data on record, last reported at $189452.0 in Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 88.69% year-over-year to $189452.0; the TTM value through Sep 2025 reached $189452.0, up 88.69%, while the annual FY2024 figure was $112020.0, 476.2% up from the prior year.
  • Cash & Equivalents reached $189452.0 in Q3 2025 per HYEX's latest filing, down from $200494.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $286939.0 in Q2 2021 and bottomed at $19441.0 in Q4 2023.
  • Average Cash & Equivalents over 5 years is $135609.4, with a median of $115138.0 recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: crashed 70.44% in 2022, then surged 476.2% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $222098.0 in 2021, then plummeted by 70.44% to $65651.0 in 2022, then crashed by 70.39% to $19441.0 in 2023, then soared by 476.2% to $112020.0 in 2024, then soared by 69.12% to $189452.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $189452.0 in Q3 2025, $200494.0 in Q2 2025, and $118798.0 in Q1 2025.